Class Action & Mass Torts

October 2021 UK’s MHRA Xeljanz Action Follows September 2021 FDA Xeljanz Drug Safety Communication Update
(Posted by Tom Lamb at Drug Injury Watch)
On September 1, 2021, we posted this article, “Xeljanz: FDA Warnings Updated: There
Continue Reading Xeljanz Risks of Cardiovascular Events, as Well as Cancers, Lead to More Xeljanz Use Limitations

Reports of Rheumatoid Arthritis Patients on Xeljanz Experiencing Secondary Neurological Adverse Events
(Posted by Tom Lamb at Drug Injury Watch)
As we have written about previously, according to the FDA, some of the generally recognized Xeljanz side
Continue Reading Xeljanz: Drug-induced Peripheral Neuropathy as Possible Xeljanz Side Effect in 2 RA Patients

A recent string of U.S. District Court decisions has clarified liability for furnishers of credit information under the Fair Credit Reporting Act (FCRA), specifically 15 U.S.C. § 1681s-2(b), in situations where consumers dispute the legal validity of a reported debt.
Continue Reading Courts Hold Contract Disputes Not Actionable Under FCRA